Proposal for MCC950 (Sigma-Aldrich catalog #SML0952)

Overview of Therapeutic Candidate:
MCC950 is a small‐molecule inhibitor originally discovered through extensive screening for its ability to block NLRP3 inflammasome activation. Chemically, it belongs to the diarylsulfonylurea class of compounds, a group known for developing molecules with high selectivity and potency in modulating immune–inflammatory pathways. Its synthesis was reported in detail in early studies that established its potent inhibitory effect on NLRP3, a cytosolic sensor that regulates the production of pro‐inflammatory cytokines including IL-1β and IL-18. MCC950 was identified by screening for molecules that specifically inhibit inflammasome assembly rather than interfering non-selectively with upstream signals. As a synthetic molecule, its structure was optimized to improve its solubility and bioavailability; indeed, its sodium salt formulation offers high water solubility that makes it suitable for both in vitro and in vivo studies. The compound has been widely used as a research tool to elucidate NLRP3 biology in various inflammatory disease models, and its chemical properties place it in a novel therapeutic class that targets intracellular inflammatory pathways. This approach is distinct from biologic agents that neutralize cytokines after their secretion, as MCC950 acts upstream by directly blocking inflammasome formation (Coll et al., 2015).

Therapeutic History:
MCC950 has been extensively evaluated in preclinical models of inflammatory and autoimmune diseases. Biochemically, it has demonstrated potent inhibition of both the canonical and non-canonical pathways of NLRP3 activation, reducing IL-1β secretion in mouse bone marrow–derived macrophages, human monocyte-derived macrophages, and peripheral blood mononuclear cells. In animal models, MCC950 has shown efficacy in conditions such as experimental autoimmune encephalomyelitis—a model for multiple sclerosis—as well as in murine models of cryopyrin-associated periodic syndromes (CAPS), where it rescued neonatal lethality by attenuating excessive inflammasome activity. Additionally, MCC950 has been proven effective in mouse models of spontaneous colitis and salt-sensitive hypertension, where its administration led to decreased systemic inflammatory cytokines and improved disease outcomes. However, to date there is no record of MCC950 being directly utilized for the treatment of Polycystic Ovary Syndrome (PCOS) or related ovarian disorders. Its extensive preclinical validation in other inflammasome-driven disease models gives strong mechanistic plausibility for its repurposing in PCOS; yet, while similar inflammatory pathways are implicated in PCOS pathogenesis—such as chronic low-grade inflammation mediated by IL-1β and IL-18—direct application in PCOS remains to be established. There is thus an opportunity for translational research to assess MCC950 in granulosa cell models of PCOS given the pre-existing preclinical safety and pharmacokinetic data in other inflammatory conditions (Perera et al., 2018; Coll et al., 2015).

Mechanism of Action:
The mechanism of action of MCC950 is well defined at the molecular level. It acts specifically on the NLRP3 inflammasome by binding directly to the NACHT domain, particularly targeting the Walker B motif. This interaction inhibits ATP hydrolysis, a critical energy-dependent step required for the conformational change and oligomerization necessary for inflammasome assembly. By preventing the formation of the active NLRP3 complex, MCC950 stops the downstream recruitment of the adaptor protein ASC and the subsequent activation of caspase-1. This cascade is essential for the proteolytic processing of the immature cytokine precursors pro-IL-1β and pro-IL-18 into their mature, secreted forms. Importantly, studies have demonstrated that MCC950 specifically reduces IL-1β and IL-18 secretion without interfering with other inflammasomes such as NLRC4, AIM2, or NLRP1, or affecting upstream Toll-like receptor (TLR) signaling. It neither affects potassium or calcium flux, nor does it disrupt the direct interactions between NLRP3 and ASC in a general manner, which underscores its specificity (Coll et al., 2015; Wu et al., 2020). Additional investigations suggest that MCC950’s binding does not perturb the priming phase of NLRP3 upregulation, but rather acts solely at the level of inflammasome assembly, which is a critical distinction compared with broader anti-inflammatory agents. Its effects on ASC oligomerization and caspase-1-mediated pyroptotic cell death have been observed consistently in cellular assays, further underlining its potential utility as an anti-inflammatory agent. The degree of inhibition consistently correlates with decreased IL-1β secretion in various cell types, and the compound has demonstrated dose-dependent inhibition with IC50 values in the low nanomolar range, making its pharmacodynamic profile highly attractive for therapeutic intervention (Coll et al., 2015; Wu et al., 2020).

Expected Effect in PCOS:
PCOS is characterized by a constellation of features including hyperandrogenism, chronic low-grade inflammation, insulin resistance (IR), and granulosa cell dysfunction. Inflammatory cytokines such as IL-1β and IL-18 have been implicated in the development of ovarian insulin resistance through their ability to activate stress kinases—for example, the c-Jun N-terminal kinase (JNK) pathway—which leads to serine phosphorylation of the insulin receptor substrate 1 (IRS-1). This serine phosphorylation impedes the proper transmission of insulin signals through the PI3K/Akt pathway, thereby inhibiting GLUT4 translocation to the plasma membrane and contributing to systemic and local insulin resistance. The central hypothesis is that by inhibiting the NLRP3 inflammasome in ovarian granulosa cells, MCC950 will reduce the secretion of IL-1β and IL-18, which in turn is expected to lower JNK-mediated IRS-1 serine phosphorylation. With a reduction in these inflammatory mediators, insulin receptor signaling through PI3K/Akt could be restored, thereby promoting proper GLUT4 translocation and insulin sensitivity. Granulosa cells express components of the inflammasome and are known to be negatively affected by chronic inflammatory signaling, leading to impaired steroidogenesis and follicle maturation. Although direct data in granulosa cells from PCOS patients is not available in the current literature, the well-documented role of NLRP3-mediated cytokine production in other cell types supports the potential translation to ovarian tissue. Moreover, the preclinical evidence demonstrating MCC950’s capacity to restore normal cytokine profiles in models of inflammatory disease provides a strong rationale that its use in PCOS could mitigate the pathological cascade linking inflammasome activation, chronic inflammation, and insulin resistance (Moustakli et al., 2025; Yang et al., 2025; Coll et al., 2015).

Overall Evaluation:
The repurposing of MCC950 for PCOS presents a promising translational opportunity based on several compelling factors. First, the high specificity of MCC950 for the NLRP3 inflammasome offers a mechanistic advantage over less selective anti-inflammatory compounds. By targeting a critical upstream node in the inflammatory cascade, it has the potential to reduce both IL-1β and IL-18 secretion and thereby attenuate downstream effects that lead to JNK activation and insulin resistance. This is particularly relevant in PCOS, where chronic inflammation is believed to drive ovarian dysfunction and metabolic disturbances. Second, the preclinical safety and favorable pharmacokinetic (PK) profile observed in animal models instill further confidence in its potential clinical utility. MCC950 has already demonstrated good oral bioavailability, metabolic stability, and a lack of significant off-target effects, which are essential parameters in drug development. Moreover, its successful application in diverse inflammatory disease models—ranging from experimental autoimmune encephalomyelitis and CAPS to colitis and hypertension—underscores its versatility as an anti-inflammatory agent (Coll et al., 2015; Perera et al., 2018; Krishnan et al., 2019).

However, several challenges remain. To date, MCC950 has not been directly evaluated in models of PCOS or in ovarian granulosa cells. This gap necessitates rigorous in vitro studies using primary granulosa cells from PCOS patients or relevant animal models of PCOS to verify that the molecular mechanisms observed in macrophages or other inflammatory models translate to ovarian tissue. Additionally, while the inhibition of NLRP3 results in reduced cytokine secretion, it is essential to confirm that this biochemical effect indeed leads to improved insulin receptor signaling at the cellular level. Detailed studies assessing downstream markers such as JNK activation, IRS-1 serine phosphorylation, PI3K/Akt pathway restoration, and GLUT4 translocation in granulosa cells are required before clinical translation. It is also important to consider that immune suppression in other contexts can create risks, such as increased susceptibility to infections; however, MCC950’s short half-life compared to biologics offers some control over such potential adverse events (Schwaid & Spencer, 2020; Wu et al., 2020).

Another strength of MCC950 lies in its mode of action, which is distinct from existing cytokine-neutralizing biologics. Current therapeutics in inflammation, like IL-1β inhibitors (anakinra, canakinumab), have shown efficacy in diseases such as CAPS but may leave IL-18-mediated pathways unchecked and are often associated with prolonged immunosuppression. MCC950, by directly preventing inflammasome assembly, offers the possibility of a more complete blockade of the pro-inflammatory cascade while allowing for a rapid withdrawal of its effects due to its shorter half-life. This characteristic is of particular interest when considering applications in metabolic diseases where fine-tuning of the inflammatory response is necessary to avoid unintended consequences on immune competence (Coll et al., 2015; Wu et al., 2020).

From a drug development perspective, the existing preclinical data on MCC950’s safety and PK profile in mouse models bolster its candidacy for repurposing in PCOS. Its high metabolic stability in liver microsomes of both human and mouse origin indicates a favorable ADME (absorption, distribution, metabolism, and excretion) profile. Furthermore, the documented low risk of cytochrome P450-mediated drug–drug interactions suggests that MCC950 could be co-administered with other therapies commonly employed in PCOS without major concerns regarding metabolic liabilities (Coll et al., 2015; Agarwal et al., 2020).

In terms of the pathophysiological rationale for PCOS, there is a growing body of evidence implicating chronic inflammation in the disruption of insulin signaling in ovarian cells. This is mediated, in part, by inflammasome-derived cytokines that promote stress kinase activation and subsequent inhibitory modifications on insulin receptor substrates. By dampening the source of these cytokines, MCC950’s mechanism of action is well aligned with the therapeutic goal of restoring normal insulin receptor/PI3K/Akt signaling in granulosa cells, which could in turn ameliorate the insulin resistance commonly observed in PCOS patients. This mechanistic hypothesis is strengthened by parallel evidence in the literature linking reduced inflammasome activity with improved insulin sensitivity in other contexts (Yang et al., 2025; Lu et al., 2023).

Nonetheless, there are caveats that must be addressed. The absence of direct evidence for MCC950’s efficacy in PCOS models remains a significant gap. Preclinical studies specifically tailored to the ovarian microenvironment, along with clinical biomarker studies in PCOS patients, will be crucial to validate the hypothesis. Additionally, while the selective inhibition of NLRP3 is an advantage, it must be noted that inflammasomes play important roles in host defense; hence, systemic inhibition might carry risks if not properly localized or timed. Strategies to achieve ovarian-specific delivery or dosing regimens that minimize systemic immunosuppression could be beneficial.

Overall, the thorough biochemical characterization and demonstrated anti-inflammatory efficacy of MCC950 across multiple disease models offer strong support for its potential repurposing in PCOS. Its ability to directly inhibit the NLRP3 inflammasome could address the underlying inflammatory drivers of insulin resistance in ovarian granulosa cells, thereby restoring normal insulin receptor signaling and improving metabolic as well as reproductive functions. The strengths of MCC950 include its high potency, selective mechanism of action, favorable preclinical PK and safety profiles, and a mechanistic approach that targets an upstream nodal point in the inflammatory pathway. However, the lack of direct evidence in PCOS models and the inherent challenges associated with systemic inflammasome inhibition represent key areas that require further investigation. In conclusion, while promising, the translation of MCC950 for treating PCOS will require dedicated studies focusing on granulosa cell function, insulin signaling, and in vivo efficacy in PCOS-specific animal models before advancing to clinical trials (Coll et al., 2015; Perera et al., 2018; Schwaid & Spencer, 2020).

References:

Agarwal, S., Pethani, J. P., Shah, H. A., Vyas, V., Sasane, S., Bhavsar, H., Bandyopadhyay, D., Giri, P., Viswanathan, K., Jain, M. R., & Sharma, R. (2020). Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor. Bioorganic & Medicinal Chemistry Letters, 30, 127571. https://doi.org/10.1016/j.bmcl.2020.127571

Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Latz, E., Kastner, D. L., Mills, K. H. G., Masters, S. L., Schroder, K., Cooper, M. A., & O’Neill, L. A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21, 248–255. https://doi.org/10.1038/nm.3806

Krishnan, S. M., Ling, Y. H., Huuskes, B. M., Ferens, D. M., Saini, N., Chan, C. T., Diep, H., Kett, M. M., Samuel, C. S., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Peter, K., Latz, E., Mansell, A. S., Sobey, C. G., Drummond, G. R., & Vinh, A. (2019). Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovascular Research, 115, 776–787. https://doi.org/10.1093/cvr/cvy252

Lu, S., Li, Y., Qian, Z., Zhao, T., Feng, Z., Weng, X., & Yu, L. (2023). Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1052756

Moustakli, E., Stavros, S., Katopodis, P., Skentou, C., Potiris, A., Panagopoulos, P., Domali, E., Arkoulis, I., Karampitsakos, T., Sarafi, E., Michaelidis, T. M., Zachariou, A., & Zikopoulos, A. (2025). Oxidative stress and the NLRP3 inflammasome: Focus on female fertility and reproductive health. Cells, 14, 36. https://doi.org/10.3390/cells14010036

Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. (2018). MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports, 8, 8840. https://doi.org/10.1038/s41598-018-26775-w

Schwaid, A. G., & Spencer, K. B. (2020). Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. Journal of Medicinal Chemistry, 64, 101–122. https://doi.org/10.1021/acs.jmedchem.0c01307

Wu, D.-B., Chen, Y.-F., Sun, Y., Gao, Q., Li, H., Yang, Z., Wang, Y., Jiang, X., & Yu, B. (2020). Target of MCC950 in inhibition of NLRP3 inflammasome activation: A literature review. Inflammation, 43, 17–23. https://doi.org/10.1007/s10753-019-01098-8

Yang, W., Ma, Y., Wu, Y., Lei, X., Zhang, J., & Li, M.-X. (2025). Study on the effects of mogroside V in inhibiting NLRP3-mediated granulosa cell pyroptosis and insulin resistance to improve PCOS. Journal of Ovarian Research. https://doi.org/10.1186/s13048-024-01563-5
